A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
← catalyst calendarSponsored by Daiichi Sankyo Co., Ltd. (industry) · 4568.T — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
25estimated
Sites
11
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-07-08 | actual | When the study began enrolling |
| Primary completion | 2023-03-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-07-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- WHO Grade II Glioma
Intervention
- Drug: DS-1001b
Primary outcomes
what the primary-completion date above is the date OFOverall response rate (ORR) assessed by Independent Efficacy Review Committee
measured Up to 24 months
Number of participants with treatment-emergent adverse events (TEAEs) during the study
measured Up to 24 months
Publications
- PMID 41206766 — linked by the registry
- PMID 35722822 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed